DARA BioSciences Inc.

Taglich Brothers is maintaining its Speculative Buy rating and its $7.15 price target on DARA BioSciences Inc. (NASDAQ: DARA) as it looks to the future of the company's pipeline drugs. Says Taglich, in the report, “DARA's lead pipeline drugs address the markets for neuropathic pain and Type 2...